The utility of postoperative radiotherapy in intermediate-risk oral squamous cell carcinoma.


Journal

International journal of oral and maxillofacial surgery
ISSN: 1399-0020
Titre abrégé: Int J Oral Maxillofac Surg
Pays: Denmark
ID NLM: 8605826

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 02 01 2020
revised: 13 04 2020
accepted: 11 06 2020
pubmed: 4 7 2020
medline: 28 1 2021
entrez: 4 7 2020
Statut: ppublish

Résumé

The effectiveness of postoperative radiotherapy (PORT) in improving outcomes remains debatable for oral squamous cell carcinoma (OSCC) patients with pathological intermediate-risk factors (IRFs) after surgery. A retrospective analysis was conducted on 432 intermediate-risk OSCC patients defined by histological reporting of close margin (<5mm), early nodal disease (pN1), depth of invasion/tumour thickness ≥5mm, perineural invasion, and/or lymphovascular invasion. Outcomes measured were disease-free survival (DFS), disease-specific survival (DSS), and overall survival (OS). PORT was associated with an improvement in 5-year DFS on univariable analysis (80% vs 71%; P=0.044), but this did not remain significant on multivariable analysis. PORT was not associated with differences in DSS or OS. The surgical salvage rate was similar in the PORT and surgery-only groups (41% vs 47%; P=0.972). Perineural invasion was found to be an independent predictor of inferior DSS (hazard ratio (HR) 2.19), DFS (HR 1.89), and OS (HR 1.97). Significantly worse outcomes were observed for patients with ≥4 concurrent IRFs. The application of PORT was associated with lower rates of recurrence, but the benefit was less apparent on mortality. Patients with perineural invasion and multiple concurrent IRFs were found to be at greatest risk, representing a subset of intermediate-risk OSCC patients who may benefit from PORT.

Identifiants

pubmed: 32616305
pii: S0901-5027(20)30214-9
doi: 10.1016/j.ijom.2020.06.006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

143-150

Informations de copyright

Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved.

Auteurs

T Liu (T)

Oral and Maxillofacial Surgery, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia; Faculty of Medicine, University of Queensland, Herston, Queensland, Australia. Electronic address: timothy.liu@health.qld.gov.au.

M David (M)

School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia.

M Batstone (M)

Oral and Maxillofacial Surgery, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia; Faculty of Medicine, University of Queensland, Herston, Queensland, Australia.

J Clark (J)

Central Clinical School, University of Sydney, Camperdown, New South Wales, Australia; Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia; Royal Prince Alfred Institute of Academic Surgery, Sydney Local Health District, Sydney, Australia.

T-H Low (TH)

Central Clinical School, University of Sydney, Camperdown, New South Wales, Australia; Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.

D Goldstein (D)

Department of Otolaryngology - Head and Neck Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.

A Hope (A)

Department of Radiation Oncology, University of Toronto and Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.

A Hosni (A)

Department of Radiation Oncology, University of Toronto and Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.

B Chua (B)

Faculty of Medicine, University of Queensland, Herston, Queensland, Australia; Radiation Oncology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH